I made this announcement to 54,210 members of the Digital Health group on LinkedIn. If you're on LinkedIn, please do join the group, which allows you to opt in to receiving these announcements in addition to connecting with thousands of other global stakeholders in digital health. Note that I will continue to update this announcement up until sending out the final version via LinkedIn. Dr. Watson, AI, has stumbled in a very costly way at the renowned MD Anderson Cancer Center. As Matthew Herper, Sr. Editor for Pharma & Healthcare at Forbes writes, MD Anderson has benched IBM's Watson in a "setback for artificial intelligence in medicine".
An artificially intelligent computer system is making breast cancer treatment recommendations on a par with those of cancer doctors, a new study reports. The IBM computer system -- called Watson Oncology -- made treatment recommendations that jibed nine out of 10 times with those of a multidisciplinary board of doctors at a top cancer hospital in India, researchers say. In cases involving more complex cancers, however, the computer did not hit that 90 percent mark. Another version of Watson famously defeated two former winners on the game show "Jeopardy!" in 2011, winning a first-place prize of $1 million. It then spends another minute reviewing all existing medical evidence regarding their particular form of cancer, said study co-author Dr. S.P. Somashekhar, chairman of the Manipal Comprehensive Cancer Center in Bengaluru, India.
Candida Vitale and the other fellows at MD Anderson's leukemia treatment center had known each other for only a few months, but they already were very tight. The nine of them shared a small office and were always hanging out on weekends. Dr. Tina Cascone demonstrates the Oncology Expert Advisor System powered by IBM Watson at the Thoracic Center at MD Anderson Hospital in Houston. She says the system provides physicians with accurate information to provide personalized cancer treatment. Rumor had it that he had finished med school in two years and had a photographic memory of thousands of journal articles and relevant clinical trials.
It's tempting to treat IBM's Watson as a cure-all: just throw some cognitive computing at the problem and you'll make everything better. That can only happen if it's well-implemented, however, and we've just seen what happens when things go awry. The University of Texas' MD Anderson Cancer Center has put its highly-touted Watson project (the Oncology Expert Advisor) on hold after an audit discovered both spending issues and an unfocused strategy that didn't meet goals. Where tech companies often foot the bill for projects like this, MD Anderson paid the $62 million for the project itself, ducking around usual procedures in the process. Former genomic medicine chair (and wife of MD Anderson's president) Lynda Chin reportedly didn't get approval from the center's IT department, and ensured that payments to IBM were just low enough to not require board approval.
If you saw the recent headlines connecting gallbladder cancer to the consumption of sugary sodas, you may not have been too surprised by the news. America's obsession with sugar has been blamed for plenty of chronic diseases in recent years, including several types of cancer. But what is it, exactly, about the sweet stuff that seems to raise a person's cancer risk? We rounded up some recent research and spoke with Carrie Daniel-MacDougall, PhD, a nutritional epidemiologist at The University of Texas' MD Anderson Cancer Center, to get the scoop. What the studies show Scientists have been studying the relationship between sugar and various cancers; some of them affect organs directly involved in the metabolism of sugar (like the liver and pancreas), while others do not.